A. Prat

Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial

M. Sylvestre, C. Larochelle, M. Pomey, 2024, Frontiers in neurology.

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.

J. Lechner-Scott, M. Slee, F. Grand'Maison, 2024, Multiple sclerosis.

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

J. Lechner-Scott, M. Slee, A. Ponsonby, 2023, Journal of neurology.

Anti‐inflammatory disease‐modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

L. Kappos, J. Lechner-Scott, M. Slee, 2018, European journal of neurology.